Recombinant Human Versican Isoform V3 His-tag Protein, CF

When Recombinant Human Versican Isoform V3 (Catalog # 3054-VN) is coated at 0.25 μg/mL, 100 μL/well, Biotinylated Hyalurinan binds with an ED50 of 0.25-1.5 ng/mL.

2 μg/lane of Recombinant Human Versican Isoform V3 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 78-89 kDa and 67-80 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Versican Isoform V3 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Versican Isoform V3 (Catalog # 3054-VN) is coated at 0.25 μg/mL, 100 μL/well, Biotinylated Hyalurinan binds with an ED₅₀ of 0.25-1.5 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Versican protein
  Leu21-Tyr646, with a C-terminal 6-His tag
• Accession #: P13611-4
• N-terminal Sequence: Leu21
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 71 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 78-89 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Versican Isoform V3 His-tag Protein, CF

• Chondroitin sulfate proteoglycan 2WGN
• Chondroitin sulfate proteoglycan core protein 2
• CSPG2
• CSPG2DKFZp686K06110
• ERVR
• GHAP
• Glial hyaluronate-binding protein
• Large fibroblast proteoglycan
• PG-M
• PG-MWGN1
• VCAN
• versican core protein
• versican proteoglycan
• Versican

Background

Versican (versatile proteoglycan; also known as PG-M, CSPG2, ERVR, GHAP, WGN, WGN1) is a 500-600 kDa, secreted member of the large aggregating chondroitin sulfate proteoglycan family, which includes aggrecan, neurocan, and brevican (1-3). The canonical sequence of human Versican (Isoform V0) is 3396 amino acids (aa) in length. It contains an N-terminal hyaluronan-binding region, two large, alternately spliced GAG attachment domains (GAG alpha and GAG beta), two EGF-like domains, a selectin-like region, and a complement regulatory protein-like domain (2). Human Versican has multiple alternative splice variants that include variations mainly in the GAG regions. This product is the Isoform V3 which includes one mutation at aa 348 (Pro to Arg) and lacks of the entire GAG domains (aa 349-3089) compared to Isoform V0. Versican is known to associate with hyaluronan (4), tenascin (5-7), fibronectin (8), fibulin (9), and CD44 (10) in the extracellular matrix that may contribute to the malignant properties of tumor cells (11). It has an anti-adhesive effect on cells, facilitating tumor migration and invasion (12). The multiple alternative splice variants of human Versican could affect cell-cell and cell-matrix adhesion (13-15), migration (16), proliferation, apoptosis (17), and mesenchymal-epithelial transition (18). The Versican gene is expressed in several different tissues, and it is over-expressed in several cancer types, including prostate (19), brain (20), ovary (21), breast (22) and melanoma (11).

1. Shinomura, T. et al. (1993) J. Biol. Chem. 268:14461.
2. Zimmermann, D. R. and E.Ruoslahti (1989) EMBO J. 8:2975.
3. Margolis, R. U. and R. K. Margolis (1994) Methods Enzymol. 245:105.
4. Lebaron, R. G. et al. (1992) J. Biol. Chem. 267:10003.
5. Perides, G. et al. (1993) Anat. Embryol. (Berl.) 188:467.
6. Aspberg, A. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92:10590.
7. Aspberg, A. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:10116.
8. Braunewell, K. H. et al. (1995) Eur. J. Neurosci. 7:805.
9. Olin, A. I. et al. (2001) J. Biol. Chem. 276:1253.
10. Kawashima, H. et al. (2000) J. Biol. Chem. 275:35448.
11. Touab, M. et al. (2002) Am. J. Pathol. 160:549.
12. Yamagata, M. et al. (1989) J. Biol. Chem. 264:8012.
13. Wu, Y. et al. (2002) J. Biol. Chem. 277:12294.
14. Zheng, P. S. et al. (2004) J. Cell Sci. 117:5887.
15. Lemire, J. M. et al. (2002) J. Cell Physiol. 190:38.
16. Mjaatvedt, C.H. et al. (1998) Dev. Biol. 202:56.
17. Sheng, W. et al. (2005) Mol. Biol. Cell. 16:1330.
18. Sheng, W. et al. (2006) Mol. Biol. Cell. 17:2009.
19. Ricciardelli, C. et al. (1998) Clin. Cancer Res. 4:963.
20. Paulus, W. et al. (1996) J. Neuropathol. Exp. Neurol. 55:528.
21. Voutilainen, K. et al. (2003) Int. J. Cancer 107:359.
22. Nara, Y. et al. (1997) Histochem. J. 29:21.

Publications for Versican (3054-VN)(1)

Publication using 3054-VN

• Jørgensen, SM;Lorentzen, LG;Hammer, A;Hoefler, G;Malle, E;Chuang, CY;Davies, MJ; The inflammatory oxidant peroxynitrous acid modulates the structure and function of the recombinant human V3 isoform of the extracellular matrix proteoglycan versican Redox biology 2023-08-01 [PMID: 37402332] (Click Chemistry, Human)

Bioinformatics

• Uniprot:
  • P13611-4()